Education
About Us
Working with TipRanks
Follow Us
Tempest Therapeutics (TPST)
NASDAQ:TPST
TPST Stock Chart & Stats
$9.54
$0.02(2.27%)
At close: 4:00 PM EST
$9.54
$0.02(2.27%)
Day’s Range― - ―
52-Week Range$5.35 - $15.73
Previous CloseN/A
Volume2.28M
Average Volume (3M)50.79K
Market Cap
$40.49M
Enterprise Value$20.24M
Total Cash (Recent Filing)$7.51M
Total Debt (Recent Filing)$8.40M
Price to Earnings (P/E)―
Beta1.64
Next Earnings
Apr 01, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.79
Shares Outstanding4,440,161
10 Day Avg. Volume57,939
30 Day Avg. Volume50,791
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)15.83
Price to Sales (P/S)0.00
P/FCF Ratio-9.05
Enterprise Value/Market Cap0.50
Enterprise Value/Revenue41.65
Enterprise Value/Gross Profit187.44
Enterprise Value/Ebitda-0.57
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentTempest recently held a successful EOP2 meeting with the FDA, reaching a broad agreement on the Phase 3 study plan, including dose schedule and primary endpoint.
EarningsTempest posted EPS of ($3.16), which was better than both the analyst's estimate and the consensus estimate.
PartnershipsContinued support from Roche is seen as further validation of amezalpat's potential in changing the 1L HCC treatment landscape.
Bears Say
Funding NeedsTempest will still require a sizable cash infusion to fully support Phase 3 development, with management indicating it would cost approximately $100 million.
Market ConditionsThere is very deep frustration with Tempest's position due to the timing of data from Roche's MORPHEUS-Liver study and unprecedented conditions of the financial markets for healthcare funding.
Tempest Therapeutics News
TPST FAQ
What was Tempest Therapeutics’s price range in the past 12 months?
Tempest Therapeutics lowest stock price was $5.35 and its highest was $15.73 in the past 12 months.
What is Tempest Therapeutics’s market cap?
Tempest Therapeutics’s market cap is $40.49M.
When is Tempest Therapeutics’s upcoming earnings report date?
Tempest Therapeutics’s upcoming earnings report date is Apr 01, 2026 which is in 145 days.
How were Tempest Therapeutics’s earnings last quarter?
Tempest Therapeutics released its earnings results on Nov 05, 2025. The company reported -$0.79 earnings per share for the quarter, beating the consensus estimate of -$3.27 by $2.48.
Is Tempest Therapeutics overvalued?
According to Wall Street analysts Tempest Therapeutics’s price is currently Overvalued.
Does Tempest Therapeutics pay dividends?
Tempest Therapeutics does not currently pay dividends.
What is Tempest Therapeutics’s EPS estimate?
Tempest Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tempest Therapeutics have?
Tempest Therapeutics has 4,440,161 shares outstanding.
What happened to Tempest Therapeutics’s price movement after its last earnings report?
Tempest Therapeutics reported an EPS of -$0.79 in its last earnings report, beating expectations of -$3.27. Following the earnings report the stock price went up 9.101%.
Which hedge fund is a major shareholder of Tempest Therapeutics?
Currently, no hedge funds are holding shares in TPST
Tempest Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 1.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.2%
Last 30 Days ▼ 8.2%
Last 30 Days ▼ 8.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.36%
12-Months-Change
Fundamentals
Return on Equity
-405.03%
Trailing 12-Months
Asset Growth
-41.94%
Trailing 12-Months
Company Description
Tempest Therapeutics
Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.
Technical Analysis
Actinium Pharmaceuticals
―
PDS Biotechnology
―
Mersana Therapeutics
―
Lantern Pharma
―
CalciMedica
―
Ownership Overview
1.26%
Insiders
3.68% Mutual Funds
9.89% Other Institutional Investors
82.13% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---